ArticleGenome research2012
Translating cancer 'omics' to improved outcomes.
Article in Genome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Discriminating high-risk cervical Human Papilloma Virus infections with urinary biomarkers via non-targeted GC-MS-based metabolomics.PloS one · 2018Trial
- Precision treatment of gastrointestinal tumours and liver disease interaction mechanisms based on multi-omics data and microbiome hubs.Frontiers in cellular and infection microbiology · 2026Review
- Challenges in Metabolite Biomarkers as Avenues of Diagnosis and Prognosis of Cancer.Journal of cancer prevention · 2024Article
- Genome-scale metabolic models applied for human health and biopharmaceutical engineering.Quantitative biology (Beijing, China) · 2023Review
- Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).Oncology letters · 2023Review
- Fused Raman spectroscopic analysis of blood and saliva delivers high accuracy for head and neck cancer diagnostics.Scientific reports · 2022Article
- Prostate cancer in omics era.Cancer cell international · 2022Article
- Computational Biology Predicts the Efficacy of Tumor Immune Checkpoint Blockade.BioMed research international · 2022Article
- Integrative Analysis of Next-Generation Sequencing for Next-Generation Cancer Research toward Artificial Intelligence.Cancers · 2021Review
- Understanding cell-cell communication and signaling in the colorectal cancer microenvironment.Clinical and translational medicine · 2021Review
- Article
- Insight updating of the molecular hallmarks in ovarian carcinoma.EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] · 2020Article
- Evaluation of MDA-MB-468 Cell Culture Media Analysis in Predicting Triple-Negative Breast Cancer Patient Sera Metabolic Profiles.Metabolites · 2020Article
- Identification of Hub Genes Related to Carcinogenesis and Prognosis in Colorectal Cancer Based on Integrated Bioinformatics.Mediators of inflammation · 2020Article
- PROMO: an interactive tool for analyzing clinically-labeled multi-omic cancer datasets.BMC bioinformatics · 2019Article
- Non-invasive Potential Circulating mRNA Markers for Colorectal Adenoma Using Targeted Sequencing.Scientific reports · 2019Article
- Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.Oncology letters · 2019Article
- Integrative analysis from multi-centre studies identifies a function-derived personalized multi-gene signature of outcome in colorectal cancer.Journal of cellular and molecular medicine · 2019Article
- Novel Approaches in Ovarian Cancer Research against Heterogeneity, Late Diagnosis, Drug Resistance, and Transcoelomic Metastases.International journal of molecular sciences · 2019Review
- Predicting stage-specific cancer related genes and their dynamic modules by integrating multiple datasets.BMC bioinformatics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The genomics era has yielded great advances in the understanding of cancer biology. At the same time, the immense complexity of the cancer genome has been revealed, as well as a striking heterogeneity at the whole-genome (or omics) level that exists between even histologically similar tumors. The vast accrual and public availability of multi-omics databases with associated clinical annotation including tumor histology, patient response, and outcome are a rich resource that has the potential to lead to rapid translation of high-throughput omics to improved overall survival. We focus on the unique advantages of a multidimensional approach to genomic analysis in this new high-throughput omics age and discuss the implications of the changing cancer demographic to translational omics research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.